Employees: 30
Size Elixiron Immunotherapeutics (Cayman) (7871.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $412M, the 496th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$113.50 on 18 Nov 2026.
Performance Over six months the shares gained 64.2%, against -21.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 6,162.4% over the last twelve months (peer median +3.4%); the operating margin is -194.2% (peer median 1.9%).
Valuation It trades at 119.7× enterprise value to sales against a peer median of 3.3× (4th most expensive of 19).
Capital Return on invested capital runs 34.9 points below its cost of capital (8.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | NT$113M | NT$50.3M | NT$803,000 | NT$25.7M |
| Revenue growth | — | +6,162% | -97% | — |
| Gross profit | NT$104M | NT$40.8M | -NT$7.18M | NT$19.7M |
| EBITDA | -NT$211M | -NT$187M | -NT$209M | -NT$117M |
| Net income | -NT$156M | -NT$1.11B | -NT$440M | NT$268M |
| Free cash flow | -NT$156M | -NT$132M | -NT$250M | -NT$106M |
| Capital expenditure | -NT$57,000 | NT$5.50M | NT$9.97M | NT$217,000 |
| Total debt | n/a | NT$24.9M | NT$1.38B | NT$778M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7871.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.1% | -9.8% | 5th lowest of 21 |
| 6-month return | +64.2% | -21.3% | highest of 21 |
| Distance from 52-week high | -38.6% | -48.8% | 7th highest of 21 |
| Revenue growth (TTM) | +6,162.4% | +3.4% | highest of 19 |
| Operating margin | -194.2% | 1.9% | 5th lowest of 19 |
| EV / Sales | 119.7× | 3.3× | 4th most expensive of 19 |
| ROIC minus cost of capital | -34.9 pp | -4.8 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $407M | -15% | -16% | 7% | 1.7× | -3.2% | +11.2% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |